Among adults with acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA) with planned ...

The rationale behind the treatment is that because genetic FXI deficiency has been linked with reduced risk of ischemic ...

FRANKFURT, Feb 5 (Reuters) - Bayer said on Thursday its experimental blood thinner cut the risk of stroke recurrence by 26% ...

Asundexian cut the risk of an additional stroke by 26% in a large Phase 3 trial without accompanying safety issues, boosting the commercial outlook for an emerging class of anti-clotting drugs.

Overlooked or underestimated risk factors may warrant more consideration in stroke prevention and epidemiology, according to ...

Stroke during pregnancy or shortly after delivery is rare, yet it can be life-threatening. Increased awareness and ...

An investigational anti-clotting medication, asundexian, has demonstrated a reduction in the risk of a second ischemic ...

Women who follow the Mediterranean diet have a lower risk of stroke, especially ischemic and hemorrhagic types, according to ...

Women who regularly follow a Mediterranean diet show a lower risk of stroke, according to a new study. View on euronews ...

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and Johnson & Johnson’s rival factor XIa inhibitor in a blockbuster indication.

Investing.com -- Bayer AG ’s experimental drug asundexian reduced the risk of secondary strokes by 26% in a late-stage clinical trial, potentially providing a growth driver for the German company as ...

A new scientific statement from the American Heart Association outlines maternal stroke risk and prevention and treatment strategies during pregnancy and postpartum.